Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Following screening visit and verification of inclusion/exclusion criteria and informed
consent, participants will undergo a multiple sleep latency test (MSLT) and polysomnogram
(PSG) assessments to confirm eligibility for randomization. Participants will be randomized
to two groups: placebo or XW10172 MR. The drug will be taken orally at bedtime for 6 weeks of
treatment that will consist of a 2-week dose escalation/titration period and a 4-week
stable-dose maintenance period. There will be a 2-week safety period following dosing.